These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 10784550)

  • 21. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling.
    Manca A; Lambert PC; Sculpher M; Rice N
    Med Decis Making; 2007; 27(4):471-90. PubMed ID: 17641141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Economic assessment, a field between clinical research and observational studies].
    Launois R
    Bull Cancer; 2003 Jan; 90(1):97-104. PubMed ID: 12609811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW; Montmartin J
    Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness in clinical trials: using multiple imputation to deal with incomplete cost data.
    Burton A; Billingham LJ; Bryan S
    Clin Trials; 2007; 4(2):154-61. PubMed ID: 17456514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incremental net benefit in randomized clinical trials.
    Willan AR; Lin DY
    Stat Med; 2001 Jun; 20(11):1563-74. PubMed ID: 11391688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.
    O'Hagan A; Stevens JW
    Stat Methods Med Res; 2002 Dec; 11(6):469-90. PubMed ID: 12516985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation in long-term clinical trials.
    Hlatky MA; Boothroyd DB; Johnstone IM
    Stat Med; 2002 Oct; 21(19):2879-88. PubMed ID: 12325104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Non-parametric methods for estimating confidence intervals around the incremental cost-effectiveness ratio].
    Petrinco M; Gregori D; Lazzarato F; Brunello F; Veltri A; Berchialla P; Pagano E
    Epidemiol Prev; 2008; 32(6):307-13. PubMed ID: 19353965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic analysis and complex randomized controlled trials.
    Delaney B
    Fam Pract; 2007 Sep; 24(4):293-4. PubMed ID: 17728291
    [No Abstract]   [Full Text] [Related]  

  • 30. On cost effectiveness and sample size in clinical trials.
    Hart AA; Dijkgraaf MG
    Pharmacoeconomics; 2004; 22(10):685-8, author reply 688-9. PubMed ID: 15244493
    [No Abstract]   [Full Text] [Related]  

  • 31. From efficacy to cost-effectiveness.
    Thompson S; Barber J
    Lancet; 1997 Dec; 350(9093):1781-2. PubMed ID: 9413495
    [No Abstract]   [Full Text] [Related]  

  • 32. From efficacy to cost-effectiveness.
    Kernick DP
    Lancet; 1997 Dec; 350(9093):1781. PubMed ID: 9413494
    [No Abstract]   [Full Text] [Related]  

  • 33. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data.
    Willan AR; Briggs AH; Hoch JS
    Health Econ; 2004 May; 13(5):461-75. PubMed ID: 15127426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomization within quality registries: a cost-effective complement to classical randomized trials.
    Eur Heart J; 2014 Jan; 35(1):1-2. PubMed ID: 24382633
    [No Abstract]   [Full Text] [Related]  

  • 35. Mega-trials for blockbusters.
    Ioannidis JP
    JAMA; 2013 Jan; 309(3):239-40. PubMed ID: 23321760
    [No Abstract]   [Full Text] [Related]  

  • 36. Adding cost to NNT: the COPE statistic.
    Maharaj R
    ACP J Club; 2008; 148(1):A8. PubMed ID: 18170986
    [No Abstract]   [Full Text] [Related]  

  • 37. A pragmatic multicentered randomized controlled trial of yoga for chronic low back pain: economic evaluation.
    Chuang LH; Soares MO; Tilbrook H; Cox H; Hewitt CE; Aplin J; Semlyen A; Trewhela A; Watt I; Torgerson DJ
    Spine (Phila Pa 1976); 2012 Aug; 37(18):1593-601. PubMed ID: 22433499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adding cost to number needed to treat: the COPE statistic.
    Maharaj R
    Evid Based Med; 2007 Aug; 12(4):101-2. PubMed ID: 17885150
    [No Abstract]   [Full Text] [Related]  

  • 39. What's cost-effective in cancer care?
    Cancer Discov; 2011 Nov; 1(6):OF1-2. PubMed ID: 22586658
    [No Abstract]   [Full Text] [Related]  

  • 40. Designed delays versus rigorous pragmatic trials: lower carat gold standards can produce relevant drug evaluations.
    Maclure M; Carleton B; Schneeweiss S
    Med Care; 2007 Oct; 45(10 Supl 2):S44-9. PubMed ID: 17909382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.